|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300072208 |
|
最近更新日期: Date of Last Refreshed on: |
2023-06-06 17:34:55 |
|
注册时间: Date of Registration: |
2023-06-06 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
乳腺癌患者骨安全管理运动干预方案的构建与效果评价 |
|
Public title: |
Construction and evaluation of bone safety management intervention program for breast cancer patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
乳腺癌患者全程骨安全管理干预方案的构建与实施效果评价 |
|
Scientific title: |
Construction and implementation of whole-course bone safety management intervention program for breast cancer patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈璐 |
研究负责人: |
刘均娥 |
|
Applicant: |
Chen Lu |
Study leader: |
Liu June |
|
申请注册联系人电话: Applicant telephone: |
+86 198 0035 3831 |
研究负责人电话: Study leader's telephone: |
+86 185 0013 6128 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
937177996@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
liujune66@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市丰台区右安门外西头条10号 |
研究负责人通讯地址: |
北京市丰台区右安门外西头条10号 |
|
Applicant address: |
Capital Medical University, Beijing, China |
Study leader's address: |
Capital Medical University, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
10000 |
研究负责人邮政编码: Study leader's postcode: |
|
|
申请人所在单位: |
首都医科大学 |
||
|
Applicant's institution: |
Capital Medical University, Beijing, China |
||
|
研究负责人所在单位: |
首都医科大学 |
||
|
Affiliation of the Leader: |
Capital Medical University, Beijing, China |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
Z2023SY035 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-05-12 00:00:00 |
||
|
伦理委员会联系人: |
马子寅 |
||
|
Contact Name of the ethic committee: |
Ma Ziyin |
||
|
伦理委员会联系地址: |
北京市丰台区右安门外西头条10号 |
||
|
Contact Address of the ethic committee: |
Capital Medical University, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 83911936 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
maziyin@ccmu.edu.cn |
|
研究实施负责(组长)单位: |
首都医科大学 |
||||||||||||||||||||||
|
Primary sponsor: |
Capital Medical University, Beijing, China |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市丰台区右安门外西头条10号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Capital Medical University, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京市自然科学基金(No.7222008) |
||||||||||||||||||||||
|
Source(s) of funding: |
Natural Science Foundation of Beijing(No.7222008) |
||||||||||||||||||||||
|
Target disease: |
Breast cancer |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
开发以运动干预为主的乳腺癌患者骨安全管理干预方案,并对其干预效果进行初步评价。 |
||||||||||||||||||||||
|
Objectives of Study: |
To develop and evaluate a bone safety management intervention program for breast cancer patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①病理诊断确诊为乳腺癌,知晓病情;②术后患者;③有基本的文字阅读能力,能够上网会使用微信等社交软件;④知情同意、自愿参与本次研究;⑤18 周岁≤年龄≤65 周岁。 |
||||||||||||||||||||||
|
Inclusion criteria |
(i) diagnosed with breast cancer (stages I–III); (ii)post-treatment (surgery, chemotherapy or radiotherapy) ; (iii)ability to read and use the social software ; (iv) signed informed consent; (v) age between 18 and 65 years old. |
||||||||||||||||||||||
|
排除标准: |
①已复发或转移;②严重心脏病(NYHA≥3),一年内心肌梗死或高血压未控制;③骨质疏松(股骨近端或腰椎t评分<-2.5或骨折);④同时服用影响钙和骨代谢的药物,如双膦酸盐、降钙素、甲状旁腺素、血清素、口服皮质类固醇>6个月,抗惊厥药苯妥英或卡马西平,延长肝素治疗;⑤其他影响钙和骨代谢的疾病,如甲亢、原发性甲状旁腺功能亢进、肾功能衰竭、慢性肝病、器官移植等;⑥其他严重疾病或者身体状况与锻炼相矛盾的;⑦在过去三个月内参加过锻炼计划。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(i) being diagnosed with another primary and/or secondary tumour or being in the metastatic stage; (ii) severe cardiac disease (NYHA ≥3), myocardial infarction within one year or uncontrolled hypertension; (iii) verified osteoporosis (proximal femur or lumbar spine T-score<-2.5 or fracture without trauma); (iv) concomitant medication affecting calcium and bone metabolism such as bisphosphonates, calcitonin, PTH, SERMs, oral corticosteroids >6 months, anticonvulsants phenytoin or carbamazepine, prolonged heparin therapy; (v) other diseases affecting calcium and bone metabolism such as hyperthyroidism, primary hyperparathyroidism, renal failure, chronic hepatic diseases, organ transplant; (vi) other severe illness or medical condition, which could be a contradiction to exercise; or (vii) to have participated in an exercise program during the previous three months. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-12-01 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2022-01-03 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由课题组成员A采用Excel软件形成随机数字表。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Team member A uses Excel software to form a random number table. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
本研究对参与者、测量者实施盲法。为了确保盲法的实施,该研究主要采取了以下措施: ①招募采用统一介绍说明,概述干预内容; ②除了干预者,其他工作人员不知晓分配情况; ③测量人员和干预人员在试验的整个过程中分开,测量人员不知晓分组情况,干预人员不参与结果测量工作; ④所有的调查人员、工作人员和研究对象都不知晓测量结果和试验结果; ⑤逐一招募,研究对象互不认识,不同组分别建立微信群。 |
|
Blinding: |
This study was blinded to the participants, the measurers. To ensure that blinding was implemented, the study focused on the following measures. (i) recruitment was done using a uniform introductory note outlining the intervention. (ii) Allocation was unknown to staff other than the interventionist. (iii) Surveyors and interventionists were separated throughout the trial, with surveyors unaware of groupings and interventionists uninvolved in outcome measurement. (iv)All investigators, staff and study participants were unaware of the measurements and trial results. (v)Recruitment was done on a case-by-case basis, study participants did not know each other, and separate WeChat groups were set up for different groups. |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResMan |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集通过问卷星,管理采用Excel |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data was collected by questionnaire star and administered by Excel |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |